Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies

F. Cassani, Antonella Tosti, F. B. Bianchi, M. Fusconi, L. Selleri, L. Baffoni, S. Veronesi, U. Volta, M. Lenzi, E. Pisi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14%); in systemic disease, the prevalence of FANA was 94% and that of anti-FANA ranged from 29% to 49% (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27%), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100% and 6/9 - 67%, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalClinical and Experimental Rheumatology
Volume5
Issue number1
StatePublished - Sep 16 1987
Externally publishedYes

Fingerprint

Antinuclear Antibodies
Diffuse Scleroderma
Nuclear Antigens
Counterimmunoelectrophoresis
Antibodies
Systemic Scleroderma
Immunodiffusion
Indirect Fluorescent Antibody Technique
Serum
Autoimmunity
Antigens
Lung

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Cassani, F., Tosti, A., Bianchi, F. B., Fusconi, M., Selleri, L., Baffoni, L., ... Pisi, E. (1987). Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies. Clinical and Experimental Rheumatology, 5(1), 23-28.

Clinical subsets of scleroderma : Relevance of fluorescent and precipitating antinuclear antibodies. / Cassani, F.; Tosti, Antonella; Bianchi, F. B.; Fusconi, M.; Selleri, L.; Baffoni, L.; Veronesi, S.; Volta, U.; Lenzi, M.; Pisi, E.

In: Clinical and Experimental Rheumatology, Vol. 5, No. 1, 16.09.1987, p. 23-28.

Research output: Contribution to journalArticle

Cassani, F, Tosti, A, Bianchi, FB, Fusconi, M, Selleri, L, Baffoni, L, Veronesi, S, Volta, U, Lenzi, M & Pisi, E 1987, 'Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies', Clinical and Experimental Rheumatology, vol. 5, no. 1, pp. 23-28.
Cassani, F. ; Tosti, Antonella ; Bianchi, F. B. ; Fusconi, M. ; Selleri, L. ; Baffoni, L. ; Veronesi, S. ; Volta, U. ; Lenzi, M. ; Pisi, E. / Clinical subsets of scleroderma : Relevance of fluorescent and precipitating antinuclear antibodies. In: Clinical and Experimental Rheumatology. 1987 ; Vol. 5, No. 1. pp. 23-28.
@article{4e814650b38944319176e27f45a73a12,
title = "Clinical subsets of scleroderma: Relevance of fluorescent and precipitating antinuclear antibodies",
abstract = "Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14{\%}); in systemic disease, the prevalence of FANA was 94{\%} and that of anti-FANA ranged from 29{\%} to 49{\%} (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27{\%}), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100{\%} and 6/9 - 67{\%}, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.",
author = "F. Cassani and Antonella Tosti and Bianchi, {F. B.} and M. Fusconi and L. Selleri and L. Baffoni and S. Veronesi and U. Volta and M. Lenzi and E. Pisi",
year = "1987",
month = "9",
day = "16",
language = "English",
volume = "5",
pages = "23--28",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1",

}

TY - JOUR

T1 - Clinical subsets of scleroderma

T2 - Relevance of fluorescent and precipitating antinuclear antibodies

AU - Cassani, F.

AU - Tosti, Antonella

AU - Bianchi, F. B.

AU - Fusconi, M.

AU - Selleri, L.

AU - Baffoni, L.

AU - Veronesi, S.

AU - Volta, U.

AU - Lenzi, M.

AU - Pisi, E.

PY - 1987/9/16

Y1 - 1987/9/16

N2 - Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14%); in systemic disease, the prevalence of FANA was 94% and that of anti-FANA ranged from 29% to 49% (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27%), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100% and 6/9 - 67%, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.

AB - Sera from 7 patients with localized and 35 with systemic scleroderma were studied for the presence of fluorescent antinuclear antibodies (FANA) (by indirect immunofluorescence on HEp-2 cells) and antibodies to extractable nuclear antigens (anti-ENA) (by immunodiffusion - ID - and counterimmunoelectrophoresis - CIE). In localized disease, antinuclear autoimmunity was limited to 1 FANA positive serum (14%); in systemic disease, the prevalence of FANA was 94% and that of anti-FANA ranged from 29% to 49% (by ID and CIE, respectively). The commonest ENA system, Scl-70, could be easily detected by CIE, in spite of the reported basic nature of the antigen. The anticentromere antibody occurred only in patients with acrosclerosis (7/26 - 27%), whereas the association of nucleolar + homogeneous FANA, as well as the anti-Scl-70, were found more frequently in diffuse scleroderma (9/9 - 100% and 6/9 - 67%, respectively). The presence of the anticentromere antibody excluded that of any anti-ENA, while a close association was found between nucleolar + homogeneous FANA and the anti-Scl-70. Pulmonary involvement was significantly more frequent in nucleolar + homogeneous FANA positive patients; moreover, in two cases the same pattern proved to predict the development of diffuse scleroderma.

UR - http://www.scopus.com/inward/record.url?scp=0023195117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023195117&partnerID=8YFLogxK

M3 - Article

C2 - 3109797

AN - SCOPUS:0023195117

VL - 5

SP - 23

EP - 28

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 1

ER -